**Connecticut HB 6669** **Disclosure**

**Xolremdi® (Mavorixafor)**

X4 Pharmaceuticals, Inc. (X4) provides the following information to Connecticut prescribers, as required by Connecticut House Bill 6669.

The pricing information below reflects X4 Wholesale Acquisition Costs (“WAC”)

for the X4 product: Xolremdi®. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the

customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

**WAC for Xolremdi®**

|  |  |  |  |
| --- | --- | --- | --- |
| PRODUCT | NDC | DOSAGE FORM AND STRENGTH | WHOLESALE ACQUISITION COST (WAC) |
| Xolremdi® (Mavorixafor) | 83296-0100-12 | Capsule 100 MG | $43,656.00 |
| Xolremdi® (Mavorixafor) | 83296-0100-60 | Capsule 100 MG | $21,828.00 |
| Xolremdi® (Mavorixafor) | 83296-0100-90 | Capsule 100 MG | $32,742.00 |

Generic versions of Xolremdi are not currently available.

**Xolremdi®** is a registered trademark of X4 Pharmaceuticals, Inc.  
Copyright© 2025 X4 All rights reserved.   
7/27/2025